Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial

ClinicalTrials.gov ID: NCT05758246

Public ClinicalTrials.gov record NCT05758246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. A multicenter, randomized, adaptive allocation clinical trial to identify the most efficacious dose of the senolytic fisetin to reduce the composite cardiovascular, respiratory, and renal sequential organ failure assessment score at 1 week, and predict the probability of success of a definitive phase III clinical trial.

Study identification

NCT ID: NCT05758246
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Minnesota; Other
Enrollment: 220 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 65 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 23, 2023 (Actual)
Primary completion: Mar 30, 2027 (Estimated)
Completion: Jun 30, 2027 (Estimated)
Last update posted: Sep 1, 2026

2023 – 2027

United States locations

U.S. sites: 10
U.S. states: 4
U.S. cities: 7

Facility	City	State	ZIP	Site status
University of Florida	Gainesville	Florida	32608	Active, not recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
Ridges	Burnsville	Minnesota	55337	Recruiting
Southdale	Edina	Minnesota	55435	Recruiting
M Health Fairview St. John's	Maplewood	Minnesota	55109	Recruiting
St. John's	Maplewood	Minnesota	55109	Recruiting
University of Minnesota	Minneapolis	Minnesota	55414	Active, not recruiting
HCMC	Minneapolis	Minnesota	55415	Recruiting
UMMC	Minneapolis	Minnesota	55455	Recruiting
University of Mississippi Medical Center	Jackson	Mississippi	39216	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05758246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Oct 2, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05758246 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →